Fortress Biotech, Inc.

DB:CNB0 Stock Report

Market Cap: €55.6m

Fortress Biotech Management

Management criteria checks 3/4

Fortress Biotech's CEO is Lindsay Rosenwald, appointed in Dec 2013, has a tenure of 10.92 years. total yearly compensation is $1.12M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 13.42% of the company’s shares, worth €7.46M. The average tenure of the management team and the board of directors is 10.8 years and 9.3 years respectively.

Key information

Lindsay Rosenwald

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage5.6%
CEO tenure10.9yrs
CEO ownership13.4%
Management average tenure10.8yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lindsay Rosenwald's remuneration changed compared to Fortress Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$1mUS$63k

-US$69m

Sep 30 2023n/an/a

-US$86m

Jun 30 2023n/an/a

-US$104m

Mar 31 2023n/an/a

-US$100m

Dec 31 2022US$1mUS$63k

-US$95m

Sep 30 2022n/an/a

-US$97m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$74m

Dec 31 2021US$3mUS$60k

-US$65m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$3mUS$59k

-US$47m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$32k

-US$40m

Sep 30 2019n/an/a

-US$45m

Jun 30 2019n/an/a

-US$51m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$2mUS$31k

-US$73m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$69m

Mar 31 2018n/an/a

-US$72m

Dec 31 2017US$2mUS$31k

-US$65m

Compensation vs Market: Lindsay's total compensation ($USD1.12M) is above average for companies of similar size in the German market ($USD475.63K).

Compensation vs Earnings: Lindsay's compensation has been consistent with company performance over the past year.

CEO

Lindsay Rosenwald (69 yo)

10.9yrs

Tenure

US$1,122,585

Compensation

Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...

Leadership Team

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman10.9yrsUS$1.12m13.42%
€ 7.5m
David Jin
CFO & Head of Corporate Development4.5yrsUS$1.32m0.039%
€ 21.9k
Michael Weiss
Executive Vice Chairman of Strategic Development & Director10.8yrsUS$962.66k4.88%
€ 2.7m
Samuel Berry
General Counsel & Corporate Secretary6.2yrsno datano data
George Avgerinos
Senior Vice President of Biologics Operations11.4yrsUS$386.49k0.16%
€ 87.9k

10.8yrs

Average Tenure

63.5yo

Average Age

Experienced Management: CNB0's management team is seasoned and experienced (10.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman15.1yrsUS$1.12m13.42%
€ 7.5m
Michael Weiss
Executive Vice Chairman of Strategic Development & Director10.9yrsUS$962.66k4.88%
€ 2.7m
Malcolm Hoenlein
Independent Director10.8yrsUS$45.03k0.021%
€ 11.5k
Stephen Nimer
Scientific Advisor7.4yrsno datano data
Dov Klein
Independent Director9.3yrsUS$120.06k0.0099%
€ 5.5k
William Sandborn
Scientific Advisor7.4yrsno datano data
J. Lobell
Independent Director18.4yrsUS$87.57k0.42%
€ 232.9k
Xiaoqin Lu
Director1.9yrsUS$40.03k0.012%
€ 6.5k
David Elliott
Scientific Advisor7.4yrsno datano data
Joel Weinstock
Scientific Advisor7.4yrsno datano data
Mark Lowdell
Member of Scientific Advisory Boardno datano datano data
Jimmie Harvey
Independent Director15.9yrsUS$67.57k0.018%
€ 10.1k

9.3yrs

Average Tenure

65yo

Average Age

Experienced Board: CNB0's board of directors are considered experienced (9.3 years average tenure).